BCBrecht Claerhout

Brecht Claerhout

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Brecht Claerhout has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 January 2014
      • Vol. 205, 823-7

    Supporting patient screening to identify suitable clinical trials.

    by Anca Bucur, Jasper Van Leeuwen, Njin-Zu Chen, Brecht Claerhout, Kristof De Schepper, David Perez-Rey, Raul Alonso-Calvo, Lina Pugliano, Kamal S. Saini

    To support the efficient execution of post-genomic multi-centric clinical trials in breast cancer we propose a solution that streamlines the assessment of the eligibility of patients for available trials. The assessment of the eligibility of a patient for a trial requires evaluating whether each eligibility criterion is satisfied and is often a time consuming and manual task. The main focus in the literature has been on proposing different methods for modelling and formalizing the eligibility criteria. However the current adoption of these approaches in clinical care is limited. Less effort has been dedicated to the automatic matching of criteria to the patient data managed in clinical care. We address both aspects and propose a scalable, efficient and pragmatic patient screening solution enabling automatic evaluation of eligibility of patients for a relevant set of trials. This covers the flexible formalization of criteria and of other relevant trial metadata and the efficient management of these representations.


    • 1 January 2013
      • Vol. 192, 980

    Analyzing SNOMED CT and HL7 terminology binding for semantic interoperability on post-genomic clinical trials.

    by Santiago Aso, David Perez-Rey, Raul Alonso-Calvo, Antonio Rico-Diez, Anca Bucur, Brecht Claerhout, Victor Maojo

    Current post-genomic clinical trials in cancer involve the collaboration of several institutions. Multi-centric retrospective analysis requires advanced methods to ensure semantic interoperability. In this scenario, the objective of the EU funded INTEGRATE project, is to provide an infrastructure to share knowledge and data in post-genomic breast cancer clinical trials. This paper presents the process carried out in this project, to bind domain terminologies in the area, such as SNOMED CT, with the HL7 v3 Reference Information Model (RIM). The proposed terminology binding follow the HL7 recommendations, but should also consider important issues such as overlapping concepts and domain terminology coverage. Although there are limitations due to the large heterogeneity of the data in the area, the proposed process has been successfully applied within the context of the INTEGRATE project. An improvement in semantic interoperability of patient data from modern breast cancer clinical trials, aims to enhance the clinical practice in oncology.

    • 1 January 2008
      • Vol. 141, 67-72

    A data protection framework for trans-European genetic research projects.

    by Brecht Claerhout, Nikolaus Forgó, Tina Krügel, Marian Arning, Georges De Moor

    The paper proposes a data protection framework for trans-European medical research projects, which is based on a technical security infrastructure as well as on organizational measures and contractual obligations. It mainly relies on pseudonymization, an internal Data Protection Authority and on a Trusted Third Party. The outcome is an environment that combines both good research conditions and an extensive protection of patients' privacy.


    • 1 January 2003
      • Vol. 95, 170-5

    Secure communication and management of clinical and genomic data: the use of pseudonymisation as privacy enhancing technique.

    by Brecht Claerhout, Georges J De Moor, Filip De Meyer

    The growing need of managing both clinical and genetic data raises important legal and ethical challenges. This article introduces some of the privacy protection problems related to genomic medicine and highlights the relevance of Trusted Third Parties and of Privacy Enhancing Techniques (PETs) in the context of e.g. research. Practical approaches based on two pseudonymisation models, for both batch and interactive data collection and exchange, are presented.